CCA
COGT icon

Catalyst Capital Advisors’s Cogent Biosciences COGT Stock Holding History

Catalyst Capital Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-149
Closed -$6K – 431
2018
Q3 		$6K Hold
149
– – ﹤0.01% 380
2018
Q2 		$9K Buy
149
+45
+43% +$2.16K ﹤0.01% 369
2018
Q1 		$5K Buy
+104
New +$4.62K ﹤0.01% 396

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Catalyst Capital Advisors's COGT Position: Q4 2018 in Review

Catalyst Capital Advisors sold out of Cogent Biosciences (COGT) in Q4 2018, closing a stake of 149 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in COGT in Q1 2018 and held it in 3 quarters. The position peaked at $9K in Q2 2018. 47 funds tracked by Wall St. Rank hold COGT as of Q4 2018.

  • Catalyst Capital Advisors reported no remaining Cogent Biosciences position as of Q4 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 149 Cogent Biosciences shares in Q4 2018, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in Cogent Biosciences in Q1 2018 and held it in 3 quarters.
  • Catalyst Capital Advisors's Cogent Biosciences position peaked at $9K in Q2 2018.
  • 47 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2018.

Based on Catalyst Capital Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.